@edreznik.bsky.social
Reposted
The largest description of cancer #cachexia to date across all tumor types and over time using data from 60,000 people. @edreznik.bsky.social redefines what we know about human cachexia integrating genetics, lab values, and treatment lines. www.medrxiv.org/content/10.1...
A health-system-scale, episode-resolved multimodal atlas of cancer cachexia
Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality. Neither the etiology of cachexia, nor its consequences on patient physiology and outcomes, are well-understood. H...
www.medrxiv.org
September 30, 2025 at 10:22 PM
The largest description of cancer #cachexia to date across all tumor types and over time using data from 60,000 people. @edreznik.bsky.social redefines what we know about human cachexia integrating genetics, lab values, and treatment lines. www.medrxiv.org/content/10.1...
Reposted
Excited to share our latest work in collaboration with the @edreznik.bsky.social lab @mskcancercenter.bsky.social, where we describe functionally dominant mitochondrial DNA mutations in patient tumors. So, what is functional dominance in mitochondrial genetics, I hear you ask?
rdcu.be/eN1jm
rdcu.be/eN1jm
Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer
Nature Genetics - Analysis of 14,106 tumor genomes highlights recurrent mutations in mitochondrial ribosomal RNA encoded within the mitochondrial genome. Mutations occur at hotspot positions and...
rdcu.be
November 3, 2025 at 11:15 AM
Excited to share our latest work in collaboration with the @edreznik.bsky.social lab @mskcancercenter.bsky.social, where we describe functionally dominant mitochondrial DNA mutations in patient tumors. So, what is functional dominance in mitochondrial genetics, I hear you ask?
rdcu.be/eN1jm
rdcu.be/eN1jm
For those of you hunting for your next position, please consider applying for a postdoctoral position in our lab. Our science is wild and exciting, and I promise to train and feed (yes, w/free food) you well. It doesn't hurt that we are on a publication hot streak.
August 8, 2025 at 3:01 PM
For those of you hunting for your next position, please consider applying for a postdoctoral position in our lab. Our science is wild and exciting, and I promise to train and feed (yes, w/free food) you well. It doesn't hurt that we are on a publication hot streak.
Reposted
🚨New Review available online
Scott M. Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context.
www.nature.com/articles/s43...
Scott M. Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context.
www.nature.com/articles/s43...
Biomarker-informed care for patients with renal cell carcinoma - Nature Cancer
Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to p...
www.nature.com
April 18, 2025 at 1:15 PM
🚨New Review available online
Scott M. Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context.
www.nature.com/articles/s43...
Scott M. Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context.
www.nature.com/articles/s43...
Reposted
🌟Technical Report online now
Amy Xie, Wesley Tansey & Ed Reznik present the tool UnitedMet that imputes metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status and metastasis or therapy outcome in kidney cancer.
www.nature.com/articles/s43...
Amy Xie, Wesley Tansey & Ed Reznik present the tool UnitedMet that imputes metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status and metastasis or therapy outcome in kidney cancer.
www.nature.com/articles/s43...
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples - Nature Cancer
Xie et al. present UnitedMet, a tool that leverages RNA–metabolite covariation to impute metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status...
www.nature.com
April 18, 2025 at 1:05 PM
🌟Technical Report online now
Amy Xie, Wesley Tansey & Ed Reznik present the tool UnitedMet that imputes metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status and metastasis or therapy outcome in kidney cancer.
www.nature.com/articles/s43...
Amy Xie, Wesley Tansey & Ed Reznik present the tool UnitedMet that imputes metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status and metastasis or therapy outcome in kidney cancer.
www.nature.com/articles/s43...
Excited to tell you about a new method from our lab, UnitedMet, which imputes metabolite levels/ isotope tracing from RNA data. It features the best first sentence I've ever written: "Comprehensively studying metabolism requires metabolite measurements." www.nature.com/articles/s43...
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples - Nature Cancer
Xie et al. present UnitedMet, a tool that leverages RNA–metabolite covariation to impute metabolite levels from transcriptomic data, and find oxidative phosphorylation associated with both BAP1 status...
www.nature.com
April 18, 2025 at 3:06 PM
Excited to tell you about a new method from our lab, UnitedMet, which imputes metabolite levels/ isotope tracing from RNA data. It features the best first sentence I've ever written: "Comprehensively studying metabolism requires metabolite measurements." www.nature.com/articles/s43...
Reposted
Really pumped to see our paper on how mtDNA mutations modify tumour biology with @edreznik.bsky.social & colleagues highlighted by the US National Cancer Institute’s Division of Cancer Biology as one of their advances of 2024! If you’re interested do check it out 😊 www.cancer.gov/about-nci/or...
Research Advances in Cancer Biology
Research projects funded by the Division of Cancer Biology have led to many new discoveries and advances in basic cancer research that continue to lay the groundwork for future clinical breakthroughs ...
www.cancer.gov
January 14, 2025 at 5:56 PM
Really pumped to see our paper on how mtDNA mutations modify tumour biology with @edreznik.bsky.social & colleagues highlighted by the US National Cancer Institute’s Division of Cancer Biology as one of their advances of 2024! If you’re interested do check it out 😊 www.cancer.gov/about-nci/or...
Reposted
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
Selective pressure for biallelic inactivation varies widely across tumor suppressor genes and is a biomarker for therapeutic response, providing new insights into Knudson’s two-hit hypothesis.
www.cell.com
December 18, 2024 at 4:07 PM
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
Selective pressure for biallelic inactivation varies widely across tumor suppressor genes and is a biomarker for therapeutic response, providing new insights into Knudson’s two-hit hypothesis.
www.cell.com
December 18, 2024 at 4:07 PM
A culmination of ~5 years of work, today our work on biallelic alterations across tumor suppressor genes is published in
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...
@cellcellpress.bsky.social With Mark Zucker, Maria Perry, and Chai Bandlamudi www.cell.com/cell/fulltex...